

## **Product datasheet for TL311320V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **MYD88 Human shRNA Lentiviral Particle (Locus ID 4615)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** MYD88 Human shRNA Lentiviral Particle (Locus ID 4615)

**Locus ID:** 4615

Synonyms: IMD68; MYD88D

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** MYD88 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001172566, NM 001172567, NM 001172568, NM 001172569, NM 002468, NM 002468.2,

NM 002468.3, NM 002468.4, NM 001172566.1, NM 001172569.1, NM 001172568.1, NM 001172567.1, BC013589, BC013589.1, NM 001365877, NM 001365876, NM 002468.5

UniProt ID: Q99836

**Summary:** This gene encodes a cytosolic adapter protein that plays a central role in the innate and

adaptive immune response. This protein functions as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. These pathways regulate that activation of numerous proinflammatory genes. The encoded protein consists of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in this gene have an increased susceptibility to pyogenic bacterial infections. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).